Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Conesa Botella, Anali ^a,b   Florence, Eric ^a   Lynen, Lutgarde ^a   Colebunders, Robert ^a,b   Menten, Joris ^a   Moreno Reyes, Rodrigo ^c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VITAMIN D;

ADULT; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VITAMIN D DEFICIENCY;

EID: 78549296767     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-7-40     Document Type: Article

References (41)

1. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004, 79:820-825.
2. Holick MF. Vitamin D deficiency. N Engl J Med 2007, 357:266-281. 10.1056/NEJMra070553, 17634462.
3. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503. 10.1016/S0140-6736(01)06580-1, 11705562.
4. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773. 10.1126/science.1123933, 16497887.
5. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007, 167:1159-1165. 10.1001/archinte.167.11.1159, 17563024.
6. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005, 48:1247-1257. 10.1007/s00125-005-1802-7, 15971062.
7. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990, 19:559-563. 10.1093/ije/19.3.559, 2262248.
8. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010, 10(4):482-96. 10.1016/j.coph.2010.04.001, 20427238.
9. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004, 29:664-673. 10.1016/j.tibs.2004.10.005, 15544953.
10. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
11. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168:1629-1637. 10.1001/archinte.168.15.1629, 2677029, 18695076.
12. Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, Msamanga GI, Hunter D, Fawzi WW. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 2010, 5:e8770. 10.1371/journal.pone.0008770, 2808247, 20098738.
13. Paul TV, Asha HS, Thomas N, Seshadri MS, Rupali P, Abraham OC, Pulimood SA, Jose A. Hypovitaminosis D and Bone Mineral Density in HIV infected Indian Men with or without antiretroviral therapy. Endocr Pract 2010, 16(4):547-53. 10.4158/EP09197.OR, 20150027.
14. Ramayo E, Gonzalez-Moreno MP, Macias J, Cruz-Ruiz M, Mira JA, Villar-Rueda AM, Garcia-Garcia JA, Gomez-Mateos JM, Lozano F, Pineda JA. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2005, 21:915-921. 10.1089/aid.2005.21.915, 16386106.
15. Fabbriciani G, De Socio GV. Efavirenz and bone health. AIDS 2009, 23:1181. 10.1097/QAD.0b013e32832bab0f, 19451795.
16. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003, 17:513-520. 10.1097/00002030-200303070-00006, 12598771.
17. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol 2009, 75:1392-1399. 10.1124/mol.108.053660, 19286836.
18. Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, Bollerslev J, Froland SS. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999, 84:145-150. 10.1210/jc.84.1.145, 9920075.
19. Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004, 48:39-48.
20. Gyllensten K, Josephson F, Lidman K, Saaf M. Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. AIDS 2006, 20:1906-1907. 10.1097/01.aids.0000244216.08327.39, 16954738.
21. Van Den Bout Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, Burger DM, Bravenboer B, Koopmans PP, Van DV. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24:1375-1382. 10.1089/aid.2008.0058, 18928396.
22. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, Magenta L, Calmy A, Vergopoulos A, Bischoff-Ferrari HA. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010, 24:1127-1134. 10.1097/QAD.0b013e328337b161, 20168200.
23. Childs K, Kadish C, Branch-Elliman W, Fishman S, Mullen M, Branch A. Vitamin D and calcium supplements reverse the secondary hyperparathyroidism that commonly occurs in HIV patients on TDF containing HAART. 15th Annual Conference of the British HIV Association, Liverpool, UK; HIV Med 2009, 10(Suppl. 1). 40 Abstract P89.
24. Rivas P, Gorgolas M, Garcia-Delgado R, az-Curiel M, Goyenechea A, Fernandez-Guerrero ML. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 2008, 9:89-95. 10.1111/j.1468-1293.2007.00525.x, 18093130.
25. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009, 27:817-824.
26. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165-2174. 10.1097/QAD.0b013e32801022eb, 17086056.
27. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High Frequency of Vitamin D Deficiency in Ambulatory HIV-Positive Patients. AIDS Res Hum Retroviruses 2008, 25(1):9-14.
28. Rosenvinge M, Gedela K, Copas A, Wilkinson A, Sheehy C, Bano G, Hay P, Pakianathan M, Sadiq S. Tenofovir-Linked hyperparathyroidism Is Independently Associated With Presence of Vitamin D Deficiency. J Acquir Immune Defic Syndr 2010, 54(5):496-9. 10.1097/QAI.0b013e3181caebaa, 20672448.
29. Moreno-Reyes R, Carpentier YA, Boelaert M, El MK, Dufourny G, Bazelmans C, Leveque A, Gervy C, Goldman S. Vitamin D deficiency and hyperparathyroidism in relation to ethnicity: a cross-sectional survey in healthy adults. Eur J Nutr 2009, 48(1):31-7. 10.1007/s00394-008-0756-1, 19030910.
30. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201. 10.1001/jama.292.2.191, 15249568.
31. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006, 42:108-114. 10.1086/498511, 16323100.
32. Thomas J, Doherty SM. HIV infection--a risk factor for osteoporosis. J Acquir Immune Defic Syndr 2003, 33:281-291.
33. Zapor MJ, Cozza KL, Wynn GH, Wortmann GW, Armstrong SC. Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 2004, 45(6):524-35. 10.1176/appi.psy.45.6.524, 15546830.
34. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004, 44:1273-1281. 10.1177/0091270004269142, 15496645.
35. Wynn GH, Zapor MJ, Smith BH, Wortmann G, Oesterheld JR, Armstrong SC, Cozza KL. Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. Psychosomatics 2004, 45(3):262-70. 10.1176/appi.psy.45.3.262, 15123854.
36. Borderi M, Vescini F, Cozzi-Lepri A, Di Caro A, Shlacht I, Cassola G, Pellizzer G, Vecchiet J, Re M, d'Arminio Monforte A. Prevalence of Hypovitaminosis D among HIV+ Patients Enrolled in a Large italian Cohort. 17th Conference on Retroviruses and Opportunistic Infections 2010, San Fransisco, California, Poster 751.
37. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000, 72:690-693.
38. Bischoff-Ferrari H. Health effects of vitamin D. Dermatol Ther 2010, 23:23-30. 10.1111/j.1529-8019.2009.01288.x, 20136906.
39. Glare PA. Pain in patients with HIV infection: issues for the new millennium. Eur J Pain 2001, 5(Suppl A):43-48. 10.1053/eujp.2001.0279, 11798217.
40. Prakash S, Shah ND. Chronic tension-type headache with vitamin D deficiency: casual or causal association?. Headache 2009, 49:1214-1222. 10.1111/j.1526-4610.2009.01483.x, 19619241.
41. Straube S, Andrew MR, Derry S, McQuay HJ. Vitamin D and chronic pain. Pain 2009, 141:10-13. 10.1016/j.pain.2008.11.010, 19084336.